YouSaid · the spoken record

Anne Wojcicki

lines on the record: 103
first: 2016-04-04
most recent: 2016-04-04
sittings or episodes: 1
sources: podcast

Every line below is reproduced as it was said and linked to the record it came from. Nothing here is summarised or generated. Directory · Search · Corrections

“And I think that's where she just canceled a conference that we were going to speak at together. And I think she had said they're focusing on making sure that they can publish.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“I think that historically, I think there's a lot of people who will say the diagnostic industry has historically not necessarily shared a lot of their data. There's a lot of trade secret in the industry. And so you can make that argument that this is just another type of, you know,”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Well, I had the philosophy that I have no business until I've won over the scientific community. And so what I'm eager to see from there is, because again, I think there's a huge amount of potential there, but I think everyone is just saying we want to see the data. Why are you?”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“But look what happened. I love the concept. I love exactly what they're trying to do. And I know Elizabeth well. I think it's, I have a ton of respect for them there in what I've said to her and what I say to everybody. Like 23andMe, when we first came out, the first stuff we did is we put out a white paper about how we're doing things. We published extensively. We didn't have a marketing person for the first six, seven years of the company because...”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“I think one, the fact that there is this consumer movement coming, I think the fact that we did generate a lot of press, our warning letter definitely generated a lot of press. And it wasn't us alone, but I think that there's this entire movement. Like anyone, I mean, you have to, like my Wall Street friends say this, like you have to be blind to not see that change is coming from this area. I mean, one of the best things that I learned when I was on Wall Street is I sat through the entire change of those days when people would say, well, people really put their credit cards online. Will Amazon really succeed? And so the same thing people are saying now, can a consumer really own their genome? And so in some ways, it's not traumatic for me that they're asking those questions because I've seen it before. It's a change.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“The main thing I see, and I always focus on the positives here, the FDA is putting in a huge effort to actually understand what is happening in Silicon Valley. So they've been doing regular sets of meetings at UCSF and Stanford coming out here understanding what people are doing, trying to better communicate how their process works, better trying to understand what...”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“So I think that look, I think that there's pros and cons of each system. And I have respect for each type of system. And there's good and bad. The thing that we had to do, we had to do an incredible amount of testing on the customer to make sure that they really understand it in an incredible amount of analytical validity to prove that the results that we're giving back are really the results, the accuracy. Well, that it's accurate and that people can understand it. They're also crazy. So there's a process.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Well, there's two different ways. There's two different paths. Like, most diagnostics on the market today, like there's lots of other companies out there, and they are regulated by Medicare. And it's a different system. And so we're regulated by FDA. So, yeah, I say, like, we are now, like, we're fans of the process that we've just gone through.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Right, and I think in part, one of the things that I point the finger at it's up to all of us, it's up to the consumer to actually take charge of that. It's almost like the voting. Like it's your responsibility.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Well, I think that's coming, of people realizing that the consumer actually is the one who should make choices in their healthcare. Right.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Yeah, we've raised a lot But I think part of it is that we could be utterly transformative to the entire industry. I mean, I think in two capacities, like one, the consumer is just being woken up to what they're actually capable of in healthcare. I will feel accomplished if there's an entire industry around us of people.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“We do a ton of research. I mean, research is a core component of 23Me. I mean, to me, that's like part of the beauty of what we do is that we're saying you have 3 billion base pairs in your genome and we don't know what they do. So let's all come together to figure that out because it's a data problem.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Alzheimer's in relative finder. People want to find relatives. We're the ones who pioneered sort of the algorithm for people finding each other. Like right now, if you join 23andMe, we compare your genome against 1.2 million people. Right. And so we're the ones who sort of pioneered how to do that and then how to make those types of maps.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Like, you know what I mean? Like, We're all from the same place. Well, it's what I say, like there's going to be a new, you know, you can essentially racially profile anyone. I can look it around the room and try to guess what everyone's from. But you really can't until you look in someone's genome. And in some ways, that's one of the problems in healthcare is that a lot of healthcare is based on assumptions of, oh, you're Korean, therefore you should do this. Or you're Jewish, you should do this. But until you look in the genome, you don't know, which is why ancestry is actually such an important part of healthcare.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Oh, all kinds of things. It was interesting. My mother had both African and Arab, and I didn't have Arab. It was really, and it was, you know, she was fascinated too. And what was interesting was that, you know, my grandmother was a genealogist, and she was wrong about a lot of things. Like, you know what I mean? Like, would you think you came from? Oh, yeah. We're all from the same place.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“And everyone has a story. I mean, that's one thing you think about is especially with the non-paternity issues over the last three years everyone finds relatives.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Was really interesting because The ancestry and the relative component is in, I mean, people talk, we got a lot of hype because of the health side, but the ancestry and the relative side is.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“No other way. We found out we had African blood, which was really interesting because we're Italian, and so it makes perfect sense a lot, quite a lot. And I had one kid and my partner, Megan, had another. And so we had very different genetics, the kids, but they had similar but very different. So it was fascinating to look at.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“You had people spit, you had spit parties, right? We did have spit parties. Well, it's also because we're telling you, like the thing I think that's interesting about what we do is it is this code within you. And until you get your genome, you just have no idea.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Well, we treat them. I mean, what we've had to do is that there's complex genetics ideas, and part of our goal of our company when I talk about the education side is make it so that genetics can be understood by anybody of any education level. Right. And that's what I'm most proud of is that we have over 90% comprehension with the test we got cleared. So like anyone with any kind of education background can go and actually. This information and understand it.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“When we're not able to do Alzheimer's. So that's what we're working through a whole process. Like, one of the things that we've had to do is show comprehension testing and show that when people get this information that they actually can understand what it means and that they can actually know exactly what to do with it.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“And so I think that's where it was really interesting to me to see all these doctors talking about, oh, consumers, they don't want their Alzheimer's. It's scary for them. But the reality is that consumers really want that information.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Which is interesting because it's one of those things that you can't get from the medical world. And I think that's one of the things that actually highlights some of the things I saw when I was on Wall Street is that what the system is providing isn't necessarily what the consumers want. And in part, I think that goes because the consumer doesn't pay the bill. The system doesn't necessarily provide what the consumer wants.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Well, I think the thing, you know, when I look back, people are customers definitely want, interestingly, the number one thing that people ever requested was Alzheimer's.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“So in that instance, we were able to downclassify and actually say there's a whole bunch, so there's 30 plus reports where we were actually able to get cleared all at once. So we did Bloom syndrome, and then they were able to say, based on what you did with there, if you can replicate that in all these other disease areas, then you don't have to go back to us for every single report, but actually you can just essentially self-certify that you've done it, the comprehension testing and the accuracy testing for all of those. So we're able to do that. So that's why we're able to be back on the market now with about 65 different reports.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“It's something that you might, it's like cystic fibrosis, but it's something that you potentially could pass down to your children. And if you and your partner both carry that, you could have an affected child. So we...”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Whatever the, right? So, you know, if I tell you you're a carrier for cystic fibrosis, if I tell your high risk for Alzheimer's, all of that actually needs to go through an approval process. And so we had to stop giving that information. We didn't have all the customers that we had before were able to keep their information, but we had to stop actually giving the information.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“What right, although it was interesting because it didn't impact, we had considerable growth even afterwards where a lot of people do want their ancestry information and they just want to learn about their genomes on their own. But we were not allowed, they wanted us to go through the FDA validation process and prove that it's accurate and that it's safe before we actually”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“We weren't allowed, so we weren't told that we couldn't sell anymore. We were told we were not allowed to interpret health information anymore for customers.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“I think it's complicated. I mean, I think, you know, if I look back on the company, it's obviously had a massive impact. I think that we're at a point two years later, we're two and a half years later where I can say, oh, it's been beneficial, we've been able to do all these things. But back at that time, it was a major shock for us.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“And so we need to comply as a medical device. So that is where it's a different set of criteria that we need to give to the FDA versus what we had been doing, which was complying under Medicare, which is called CLIA.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“English for people. So, the easiest way I explain it is that there's two ways diagnostic tests are regulated. Diagnostic tests in this country can either be regulated by Medicare, or they can be regulated by the FDA. And so for lots of reasons, but in large part because we're direct to consumer, we are regulated by the FDA. And so the FDA came to us and said, you are a medical device.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“And to me the beauty of genetics and especially having this information on everyone and having it not necessarily in a crisis is that it can potentially be sort of a missing piece in your health history that helps you prevent or helps you better guide your care. So factor five, for instance, is something where we've had a number of different people come and talk to us about, wow, that actually the fact that we had that ahead of time and that then we were able to mention that to the physician had a big impact on us”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“I called you up and I said that you have the factor five mutation, which makes you higher risk for blood clots, which could be associated with having.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Well, so I'd say two things like one, in some ways, people just love. Knowing about themselves. And I think there's absolutely one of the things the science community, I think, has missed is that in some ways, just teaching people about themselves, like, why do you have brown eyes? Like, why is it like, and understanding, like, oh, do you could you potentially have children with blue eyes? Like, that's just interesting for people to understand and understand why they are. I would say there's also lots of really interesting health information that people learned on our old product and that they're actually learning today, but things like, are you a carrier for cystic fibrosis? Or are you, you know, potentially lactose intolerant? There's those types of genetic variants and some of the stuff that we used to have, like for Alzheimer's and such, that we're working on trying to see could we ever get those back?”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“And what we found too is that then people can understand that. Like we talked about that actually at your conference, like where we spoke specifically about things like the asparagus and the peat, is that people can all relate to that. Whereas if I come and I say, hey, here's the latest literature on Parkinson's, that's going to appeal to a certain crowd. But if I say like, hey, we did a study on, are you a morning person or a night person? Everyone in some ways can relate to that kind of topic.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Well, but for me, part of it is like your genome is not just about health. Health, and that's one of the misperceptions that people had is people would come to me and say, Oh, I don't know, I don't want to know the day I'm going to die. I don't want to know what diseases I'm going to die from. And part of me is genetics has a bad rap in that capacity. Like your genetics is a digital reflection of you. So it's this long tail, it's a beautiful long tale of humanity of all this diversity that's out there, all the really interesting things. Like, why are some people so exceptional at sports or at math or in different capacities? And a lot of that probably comes out from different things in our genome. And so we want to understand.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Is that the average individual, if I tell you, oh, you know, do you want your genetic information, people just have absolutely no idea what would they even do with it? So there was a massive education that we've had to actually do.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Doing there's sort of what we said like the big three back in the time there were two other companies that were really doing this as well. And I think it's early. I think the challenge here is that people don't necessarily know why they would ever want their genome.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“One of our events. That was memorable. Thank God we weren't related. So I think without a doubt, we've been early, but I think about it”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Since Drive to get people online. How are them also come together Was it too early? Because one of the things you did, which I thought was interesting, is you did these spit tests, you had a lot of celebrity spit tests and where people came from. And I remember doing one with Rupert Murdoch at one of our events. That was memorable. Thank God we weren't related. Phew. And it was full of useful information. We'll talk about the personal thing that happened to me too later. But you were very early trying to popularize this idea of healthcare. And you had trouble with the FDA. Talk a little bit about that. Talk a little bit about it.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“To do With the FDA. This was the initial idea. And it remains the same idea. Yeah, I mean, it's one of the things my board members will say is that the idea and the vision of the company has not changed since we started, is that it was really about how is it that like, and I remember, well, I mean, there's all kinds of ways that 23me came together, but it was idea if I can empower people, if I can in some ways, you know, imitate some of the things that I saw going on.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“If the scientists are that excited and they're saying, like, this is one of the greatest revolutions of our time, we'll let all the people be part of this because we're essentially, to me, it's like there's this amazing mysterious code that's inside every single one of us. Don't you want to know what it means? Like I do. And that's why NIH is putting billions of dollars into trying to understand and decode that genome. And so what 23andMe is trying to do is give people an opportunity to learn about themselves.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Because you So, there's two elements for me that were really important. So, one, I think genetics is so fundamental to you and who you are. If you think about like in some ways we got lucky in the capacity of like something that a technology that's as fundamental as looking in the mirror, like it's not everything about you, but it's essentially, it's like your core structure. It's what you come from. So the fact suddenly when I was investing on Wall Street and in 2005, I saw that there was an introduction of a new kind of technology where you could get access to your genome-wide information. You could get access to your entire genome pretty cheaply. And it suddenly, like when I would do diligence on it and I would call around to people and people said, for the first time in our lives, like the excitement of what is going to happen is palpable. People are so excited about the potential of what's going to come with this genomics revolution. So I saw two avenues here. One, I want to be part of it. I want my genome. I want to see what's coming. Like I totally want to be part of it. And two,”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“We were, but like, and I realized for me, it was because my entire life I was raised this way. I was always raised to question. I never go to a doctor and just get one opinion. I always am asking questions. Like I never just like, I'll get lots of prescriptions and I don't fill half of them. Not because I want to know. And like I want to, and I question. Well, yeah, do I really need to take that?”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Well, and the whole system, I think, actually makes you feel dumb. Like, I always laugh in some ways, like you have branded names like Tylenol and then you have a cedamineophene, which is hard to say. Like in some ways, like the system, there's complicated names all over the place. Like it's hard to know there's an intimidating white coat. And so for me, it was about I actually want the consumer. The consumer and you asking for your data, you're the big loophole in healthcare. Like you're actually in charge of yourself, but no one actually tells you you're in charge. To me, it almost is like a communist society where people are so used to being told what they should and they should not do and what worked in some ways trying to do was they're trying to wake people up to the fact that they're actually responsible for their own health.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“They didn't want you to, but she was just proactive. She always knew. She was never just going to take a medicine and not actually know why it was. And so when I started researching healthcare and started realizing more and more that most people are not asked ever what they really want and that you're not actually really part of the decision process.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“She was a reporter as well. But even in my medical record, it said, you know, as everyone in this office knows, this mother tends to be irrational. And that was just kind of the norm for us, is that like it was just seen as like you wanted to be asked questions. You ask questions like you want to be the one person”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“Well, I think there was two elements. I think that, for one, it was being on Wall Street and actually seeing how it worked and having like my background, like you talked about my family, like my family is an unusual family. And my mother was always a kind of crazy advocate for our health. Right. Like for me, it was very normal that we were kicked out of doctor's offices, that we were kicked out of. There's all kinds of seas doing that. There's all kinds of people who would not want to work with this on health because she was just always questioning and even in my report.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT
“So everything is different in healthcare because you're not actually the customer. And to me, that's actually the main decision. I'm always shocked when I ask people the question, do they actually know what's going on? And there was a study that I was just looking at where it said, you know, roughly 50% of people go in for a procedure and they don't actually know why they're getting it and what the alternatives were. And imagine the analogy of you going and buying a car and walking into the first car dealership and they say, here's your Honda and it's $25,000. And you're like, great, I'll take it. Like that just never would happen in this day and age.”
2016-04-04 · Decoder with Nilay Patel · Recode Decode: Anne Wojcicki, CEO, 23andMe · IDENTIFIED FROM THE TRANSCRIPT